In CRC cohort, patients using DPP4 inhibitor only (n = 356) had HR of 0.87 (95% CI: 0.75‐1.00, P = 0.055) while patients with combined use of DPP4 inhibitors and metformin (n = 452) showed HR of 0.77 (95% CI: 0.67‐0.89, P = 0.003). Here, DPP4 is linked to colorectal carcinoma.